Adnan Khattak

发表

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.

C. Coens, A. van den Eertwegh, V. Atkinson, 2024, The Lancet. Oncology.